Embolic protection devices for transcatheter aortic valve replacement

Area of Science:

• Cardiology
• Neurology
• Medical Devices

Background:

• Transcatheter aortic valve replacement (TAVR) is a key treatment for severe aortic valve stenosis, particularly in elderly, high-risk patients.
• Expanding TAVR to younger, lower-risk populations necessitates minimizing perioperative risks, including cerebrovascular events.

Purpose of the Study:

• To review the incidence and mechanisms of neurological events during TAVR.
• To analyze clinical outcomes and imaging findings associated with embolic protection device (EPD) use.
• To assess the efficacy of EPDs in reducing neurological complications during TAVR.

Main Methods:

• Literature review of studies on TAVR-associated neurological events.
• Analysis of clinical trials evaluating EPDs (Embrella, TriGuard, Sentinel, Embol-X).
• Examination of imaging findings (MRI) and clinical outcomes related to EPD use.

Main Results:

• Published results indicate EPDs may reduce the volume and size of silent ischemic brain lesions post-TAVR on MRI.
• EPDs have not yet demonstrated a significant reduction in the incidence of new brain lesions or new neurological events.
• The effectiveness of EPDs in preventing transient ischemic attacks/strokes during TAVR remains inconclusive.

Conclusions:

• While EPDs show potential in mitigating silent ischemic brain lesions during TAVR, their clinical benefit in preventing overt neurological events needs further validation.
• Patient selection is critical for optimizing the benefits of EPDs.
• Randomized controlled trials are essential to definitively establish the clinical impact of EPDs in TAVR procedures.